DOCSLIB.ORG

Warfarin Sensitivity Related to CYP2C9, CYP3A5, ABCB1 (MDR1) and Other Factors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Warfarin Sensitivity Related to CYP2C9, CYP3A5, ABCB1 (MDR1) and Other Factors The Pharmacogenomics Journal (2004) 4, 40–48 & 2004 Nature Publishing Group All rights reserved 1470-269X/04 $25.00 www.nature.com/tpj ORIGINAL ARTICLE Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors M Wadelius1,4 ABSTRACT 1 The required dose of the oral anticoagulant warfarin varies greatly, and KSo¨rlin overdosing often leads to bleeding. Warfarin is metabolised by cytochrome 2 O Wallerman P450 enzymes CYP2C9, CYP1A2 and CYP3A. The target cell level of warfarin J Karlsson1 may be dependent on the efflux pump P-glycoprotein, encoded by the Q-Y Yue3 adenosine triphosphate-binding cassette gene ABCB1 (multidrug resistance PKE Magnusson2 gene 1). Genetic variability in CYP2C9, CYP3A5 and ABCB1 was analysed in 2 201 stable warfarin-treated patients using solid-phase minisequencing, C Wadelius pyrosequencing and SNaPshot. CYP2C9 variants, age, weight, concurrent H Melhus1 drug treatment and indication for treatment significantly influenced warfarin dosing in these patients, explaining 29% of the variation in dose. CYP3A5 did 1Department of Medical Sciences, Clinical not affect warfarin dosing. An ABCB1 haplotype containing the exon 26 Pharmacology, University Hospital, Uppsala, Sweden; 2Department of Genetics and Pathology, 3435T variant was over-represented among low-dose patients. Thirty-six Medical Genetics, Rudbeck Laboratory, Uppsala, patients with serious bleeding complications had higher prothrombin time Sweden; 3Medical Products Agency, Uppsala, international normalised ratios than 189 warfarin-treated patients without Sweden serious bleeding, but there were no significant differences in CYP2C9, CYP3A5 or ABCB1 genotypes and allelic variants. Correspondence: The Pharmacogenomics Journal (2004) 4, 40–48. doi:10.1038/sj.tpj.6500220 M Wadelius, Department of Medical Published online 16 December 2003 Sciences, Clinical Pharmacology, University Hospital, SE-751 85 Uppsala, Sweden. Keywords: warfarin; bleeding; CYP2C9; CYP3A5; ABCB1; MDR1 Tel: þ 46 18 611 49 45 Fax: þ 46 18 51 92 37 E-mail: [email protected] 4Temporary address: The Wellcome Trust Sanger Institute, Wellcome Trust Genome INTRODUCTION Campus, Hinxton, Cambridge CB10 1SA, UK. Nearly 1% of the Swedish population is treated with the oral anticoagulant Tel: þ 44 1223 49 47 09. warfarin. The indications for treatment include atrial fibrillation, heart valve prosthesis, recurrent stroke, deep vein thrombosis and pulmonary embolism.1 Interindividual variation in the response to warfarin and a narrow therapeutic range are two of the factors that make warfarin therapy difficult to handle. In all, bleeding complication during treatment with warfarin is the most common adverse drug reaction with a fatal or disabling outcome.2,3 Warfarin is a coumarin derivative that interferes with the recycling of vitamin K in the liver.2 Vitamin K is involved in the carboxylation of the precursor proteins for the coagulation factors II, VII, IX and X. In the presence of warfarin, the activity of these components in the blood is lowered by around 10–40% and coagulation is inhibited.3,4 The effect is delayed until dysfunctional coagulation factors have been synthesised, which takes 4–5 days.4 Patients treated with warfarin are monitored by prothrombin time (PT) expressed as an international normalised ratio (INR). PT INR measures the sum of activity of the vitamin K- Received: 09 July 2003 dependent coagulation factors II, VII and X. For most indications, the ideal PT Revised: 03 October 2003 4–6 Accepted: 14 October 2003 INR value lies between 2.0 and 3.0. One exception is heart valve prosthesis, Published online 16 December 2003 which requires a higher PT INR. Warfarin related to CYP2C9, CYP3A5 and ABCB1 (MDR1) M Wadelius et al 41 The dose requirement of warfarin varies more than 10-fold hepatocytes, which indicates that warfarin is a P-GP between patients.7 In general, women need lower doses than substrate in the liver.27 In theory, low P-GP activity in men.4 A high dietary intake of vitamin K leads to a higher hepatocytes may lead to a high level of warfarin in the target dose requirement, while old age is associated with lower cell, causing warfarin sensitivity in some people. doses.8–11 Diseases that increase the sensitivity to warfarin The ABCB1 gene, also called the multidrug resistance gene include liver dysfunction impairing the synthesis of coagu- 1 (MDR1), encodes P-GP. There are many known poly- lation proteins, hypermetabolic states that increase the morphisms in ABCB1: for example, À12T4C in exon 1 in clearance of coagulation factors and congestive heart failure the 50 untranslated region, À1G4A at the initiation of that alters the distribution of warfarin.3,6,11 Warfarin is translation in exon 2, 1199G4A in exon 11 leading to highly bound to serum albumin, which in combination amino-acid change S400N, 1236C4T in exon 12 at a wobble with its extensive cytochrome P450 (CYP) metabolism and position G412G, 2677G4TorG4A in exon 21 leading to narrow therapeutic range makes warfarin susceptible to drug A893S or T, and in exon 26 two polymorphisms at wobble interactions.12 positions, 3396C4T A1132A and 3435C4T I1145I.28,30 An asymmetric carbon in the warfarin molecule gives rise Polymorphisms of ABCB1 are suggested to be important to the enantiomeric forms S- and R-warfarin.13 Both for variability in drug bioavailability, but the pharmacolo- enantiomers are eliminated extensively via hepatic metabo- gical implication of these polymorphisms has not been fully lism with a low extraction ratio. The S-form is a 3–5 times established.30 more potent vitamin K antagonist than the R-form.6,7 Haemorrhage is the most common adverse reaction to CYP2C9 is the main enzyme responsible for metabolism of coumarin anticoagulants, and a great under-reporting of the active S-warfarin,7,13 which renders the genetic variation these events is believed to exist.3,31 Swedish studies have of this metabolic pathway extremely important.14 In shown that 4.5% of warfarin-treated patients experience addition to the CYP2C9*1 wild-type allele, at least 11 major bleeding and 0.5% suffer fatal complications.31 The variant alleles are known to exist (http://www.imm.ki.se/ risk of bleeding is 10 times higher during the first month cypalleles/ in September 2003). The most common variants compared to after the first year.5 There is a clear relationship CYP2C9*2 (430C4T, R144C) and CYP2C9*3 (1075A4C, between haemorrhage and the intensity of treatment, with I359L) generate enzymes with impaired hydroxylation of PT INR elevation being a strong predictor.3,5,10,32 Age, S-warfarin due to amino-acid changes, and several studies concurrent medication, specific comorbid conditions, espe- have shown that these variants have an effect on warfarin cially cerebrovascular, kidney, heart and liver disease as well dose requirement.7,11,15–24 as prosthetic heart valves, are independent risk factors.5,32 R-warfarin is mainly metabolised by the CYP enzymes Several studies suggest that patients with CYP2C9 variant CYP1A2 and CYP3A, with CYP3A likely to be the most alleles have a higher incidence of bleeding complications important.13 CYP3A activity is derived from CYP3A4 and than carriers of the wild-type genotype.15,16,20,22 The risk of CYP3A5 that have similar substrate specificities. CYP3A5 is haemorrhage must always be weighed against the preven- considered to be 17–50% of the total CYP3A content in the tion of thromboembolism, and in most patients the livers of people that express it.25,26 There is considerable preventive effect outweighs the risk of bleeding.4,32 intra- and interindividual variation in CYP3A4 enzyme The aim of the study was to identify factors that influence activity, and even though numerous polymorphisms have the effect of warfarin and the required dose. Warfarin dose been found, the molecular basis of this is not yet under- requirement was compared to genetic variation of CYP2C9, stood. On the other hand, CYP3A5 exists in distinct fast and CYP3A5 and ABCB1, age, gender, weight, smoking, indica- slow variants,25 and is therefore worth studying even if it is tion for treatment, and concurrent medication. In the case– less abundant than CYP3A4. CYP3A5*1 encodes an active control part, we studied these factors in relation to warfarin enzyme, whereas CYP3A5*3 (6986A4G) and CYP3A5*6 bleeding. (14690G4A) are inactive due to splicing defects. The CYP3A5*3 allele is the most common cause of low CYP3A5 functionality in Caucasians, while CYP3A5*6 is rarely found. RESULTS There is preliminary evidence that P-glycoprotein (P-GP) Dose Requirement contributes to warfarin disposition.27 P-GP belongs to a class The first aim was to identify factors that influence the of adenosine triphosphate-binding cassette (ABC) transport required dose of warfarin. The patients were recruited in proteins.28 It serves as a potent efflux pump for a wide 2000, when they were 28–88 years old (Table 1). They had variety of lipophilic compounds that are frequently CYP3A stable PT values, and had been treated with warfarin for substrates.29 P-GP is expressed in tissues such as the between 2.4 months and 26 years (median 2 years). intestine, liver, kidney, blood–brain barrier and placenta.28 Individual warfarin dose requirement varied between 4.5 Warfarin is well absorbed from the intestine with over 90% and 77.25 mg per week. The most frequent indications for bioavailability, making it unlikely that intestinal P-GP anticoagulation were atrial fibrillation, heart valve prosthe- affects the absorption of warfarin
Load more

Recommended publications
  • Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid
    Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 231 _____________________________ _____________________________ Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21 BY JOHAN BYLUND ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2000 Dissertation for the Degree of Doctor of Philosophy (Faculty of Pharmacy) in Pharmaceutical Pharmacology presented at Uppsala University in 2000 ABSTRACT Bylund, J. 2000. Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid: Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from Faculty of Pharmacy 231 50 pp. Uppsala. ISBN 91-554-4784-8. Cytochrome P450 (P450 or CYP) is an enzyme system involved in the oxygenation of a wide range of endogenous compounds as well as foreign chemicals and drugs. This thesis describes investigations of P450-catalyzed oxygenation of prostaglandins, linoleic and arachidonic acids. The formation of bisallylic hydroxy metabolites of linoleic and arachidonic acids was studied with human recombinant P450s and with human liver microsomes. Several P450 enzymes catalyzed the formation of bisallylic hydroxy metabolites. Inhibition studies and stereochemical analysis of metabolites suggest that the enzyme CYP1A2 may contribute to the biosynthesis of bisallylic hydroxy fatty acid metabolites in adult human liver microsomes. 19R-Hydroxy-PGE and 20-hydroxy-PGE are major components of human and ovine semen, respectively. They are formed in the seminal vesicles, but the mechanism of their biosynthesis is unknown. Reverse transcription-polymerase chain reaction using degenerate primers for mammalian CYP4 family genes, revealed expression of two novel P450 genes in human and ovine seminal vesicles.
    [Show full text]
  • Synonymous Single Nucleotide Polymorphisms in Human Cytochrome
    DMD Fast Forward. Published on February 9, 2009 as doi:10.1124/dmd.108.026047 DMD #26047 TITLE PAGE: A BIOINFORMATICS APPROACH FOR THE PHENOTYPE PREDICTION OF NON- SYNONYMOUS SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN CYTOCHROME P450S LIN-LIN WANG, YONG LI, SHU-FENG ZHOU Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing 100191, P. R. China (LL Wang & Y Li) Discipline of Chinese Medicine, School of Health Sciences, RMIT University, Bundoora, Victoria 3083, Australia (LL Wang & SF Zhou). 1 Copyright 2009 by the American Society for Pharmacology and Experimental Therapeutics. DMD #26047 RUNNING TITLE PAGE: a) Running title: Prediction of phenotype of human CYPs. b) Author for correspondence: A/Prof. Shu-Feng Zhou, MD, PhD Discipline of Chinese Medicine, School of Health Sciences, RMIT University, WHO Collaborating Center for Traditional Medicine, Bundoora, Victoria 3083, Australia. Tel: + 61 3 9925 7794; fax: +61 3 9925 7178. Email: [email protected] c) Number of text pages: 21 Number of tables: 10 Number of figures: 2 Number of references: 40 Number of words in Abstract: 249 Number of words in Introduction: 749 Number of words in Discussion: 1459 d) Non-standard abbreviations: CYP, cytochrome P450; nsSNP, non-synonymous single nucleotide polymorphism. 2 DMD #26047 ABSTRACT Non-synonymous single nucleotide polymorphisms (nsSNPs) in coding regions that can lead to amino acid changes may cause alteration of protein function and account for susceptivity to disease. Identification of deleterious nsSNPs from tolerant nsSNPs is important for characterizing the genetic basis of human disease, assessing individual susceptibility to disease, understanding the pathogenesis of disease, identifying molecular targets for drug treatment and conducting individualized pharmacotherapy.
    [Show full text]
  • I Copyright® Ariel R. Topletz, 2013
    Copyright® Ariel R. Topletz, 2013 i The Relative Importance of CYP26A1 and CYP26B1 in Mediating Retinoid Homeostasis: Studies on the Formation, Elimination and Biological Activity of All-trans-Retinoic Acid Metabolites Ariel R. Topletz A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2013 Reading Committee: Nina Isoherranen, Chair Jashvant D Unadkat Joanne Wang Program Authorized to Offer Degree: Department of Pharmaceutics ii University of Washington Abstract Ariel R. Topletz Chair of the Supervisory Committee: Associate Professor Nina Isoherranen Department of Pharmaceutics All-trans-retinoic acid (atRA), the active metabolite of Vitamin A (retinol), is an essential nutrient during both fetal development and adult life. The concentration of atRA within a cell is tightly regulated by the synthesis and elimination of atRA. One of the major elimination pathways for atRA is oxidation, predominantly by the cytochrome P450s CYP26A1 and CYP26B1 that efficiently hydroxylate atRA. The role of both CYP26A1 and CYP26B1 is believed to be to inactivate atRA, and both are essential for correct fetal development. It is not known whether both enzymes play crucial roles during adult life. In this work, the differences in the catalytic efficiency of CYP26A1 and CYP26B1 and the metabolites formed from atRA by CYP26A1 and CYP26B1 were explored. The subsequent metabolism and the activity of atRA metabolites were also evaluated. CYP26A1 was determined to form 4-OH-RA from atRA more efficiently (Km = 50 nM, Clint = 190 µL/min/pmoles P450) than CYP26B1 (Km = 19 nM, Clint = 43 µL/min/pmoles P450). In addition, formation of 4-OH-RA by CYP26A1 was stereoselective resulting in formation of (4S)-OH-RA whereas no significant stereoselectivity in 4-OH-RA formation by CYP26B1was observed.
    [Show full text]
  • The Transcriptomic Landscape of Prostate Cancer Development and Progression: an Integrative Analysis
    cancers Article The Transcriptomic Landscape of Prostate Cancer Development and Progression: An Integrative Analysis Jacek Marzec 1,† , Helen Ross-Adams 1,*,† , Stefano Pirrò 1 , Jun Wang 1 , Yanan Zhu 2, Xueying Mao 2, Emanuela Gadaleta 1 , Amar S. Ahmad 3, Bernard V. North 3, Solène-Florence Kammerer-Jacquet 2, Elzbieta Stankiewicz 2, Sakunthala C. Kudahetti 2, Luis Beltran 4, Guoping Ren 5, Daniel M. Berney 2,4, Yong-Jie Lu 2 and Claude Chelala 1,6,* 1 Bioinformatics Unit, Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK; [email protected] (J.M.); [email protected] (S.P.); [email protected] (J.W.); [email protected] (E.G.) 2 Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK; [email protected] (Y.Z.); [email protected] (X.M.); solenefl[email protected] (S.-F.K.-J.); [email protected] (E.S.); [email protected] (S.C.K.); [email protected] (D.M.B.); [email protected] (Y.-J.L.) 3 Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK; [email protected] (A.S.A.); [email protected] (B.V.N.) 4 Department of Pathology, Barts Health NHS, London E1 F1R, UK; [email protected] 5 Department of Pathology, The First Affiliated Hospital, Zhejiang University Medical College, Hangzhou 310058, China; [email protected] 6 Centre for Computational Biology, Life Sciences Initiative, Queen Mary University London, London EC1M 6BQ, UK * Correspondence: [email protected] (H.R.-A.); [email protected] (C.C.) † These authors contributed equally to this work.
    [Show full text]
  • Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives
    pharmaceuticals Article Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives Subrata Deb * , Anthony Allen Reeves and Suki Lafortune Department of Pharmaceutical Sciences, College of Pharmacy, Larkin University, Miami, FL 33169, USA; [email protected] (A.A.R.); [email protected] (S.L.) * Correspondence: [email protected] or [email protected]; Tel.: +1-224-310-7870 or +1-305-760-7479 Received: 9 June 2020; Accepted: 20 July 2020; Published: 23 July 2020 Abstract: Vitamin D3 is an endogenous fat-soluble secosteroid, either biosynthesized in human skin or absorbed from diet and health supplements. Multiple hydroxylation reactions in several tissues including liver and small intestine produce different forms of vitamin D3. Low serum vitamin D levels is a global problem which may origin from differential absorption following supplementation. The objective of the present study was to estimate the physicochemical properties, metabolism, transport and pharmacokinetic behavior of vitamin D3 derivatives following oral ingestion. GastroPlus software, which is an in silico mechanistically-constructed simulation tool, was used to simulate the physicochemical and pharmacokinetic behavior for twelve vitamin D3 derivatives. The Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) Predictor and PKPlus modules were employed to derive the relevant parameters from the structural features of the compounds. The majority of the vitamin D3 derivatives are lipophilic (log P values > 5) with poor water solubility which are reflected in the poor predicted bioavailability. The fraction absorbed values for the vitamin D3 derivatives were low except for calcitroic acid, 1,23S,25-trihydroxy-24-oxo-vitamin D3, and (23S,25R)-1,25-dihydroxyvitamin D3-26,23-lactone each being greater than 90% fraction absorbed.
    [Show full text]
  • MOL #76356 1 an Inducible Cytochrome P450 3A4-Dependent
    Molecular Pharmacology Fast Forward. Published on December 28, 2011 as DOI: 10.1124/mol.111.076356 Molecular PharmacologyThis article Fast has not Forward. been copyedited Published and formatted. on TheDecember final version 28, may 2011 differ asfrom doi:10.1124/mol.111.076356 this version. MOL #76356 An Inducible Cytochrome P450 3A4-dependent Vitamin D Catabolic Pathway Zhican Wang, Yvonne S. Lin, Xi Emily Zheng, Tauri Senn, Takanori Hashizume, Michele Scian, Leslie J. Dickmann, Sidney D. Nelson, Thomas A. Baillie, Mary F. Hebert, David Blough, Downloaded from Connie L. Davis, Kenneth E. Thummel molpharm.aspetjournals.org Departments of Pharmaceutics (Z.W, Y.S.L., X.E.Z., T.S., K.E.T.), Medicinal Chemistry (M.S., at ASPET Journals on September 24, 2021 S.D.N, T.A.B.), Pharmacy (M.F.H., D.B.), and Division of Nephrology (C.L.D.), University of Washington, Seattle, WA, USA; Pharmacokinetics Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd, Japan (T.H.); Biochemistry and Biophysics Group, Department of Pharmacokinetics and Drug Metabolism, Amgen, Seattle, WA, USA (L.J.D). 1 Copyright 2011 by the American Society for Pharmacology and Experimental Therapeutics. Molecular Pharmacology Fast Forward. Published on December 28, 2011 as DOI: 10.1124/mol.111.076356 This article has not been copyedited and formatted. The final version may differ from this version. MOL #76356 Running Title Page Running title: Metabolism of 25-hydroxyvitamin D3 by CYP3A4 Corresponding author: Kenneth Thummel, Ph.D. Department of Pharmaceutics, Box 357610
    [Show full text]
  • Robert Foti to Cite This Version
    Characterization of xenobiotic substrates and inhibitors of CYP26A1, CYP26B1 and CYP26C1 using computational modeling and in vitro analyses Robert Foti To cite this version: Robert Foti. Characterization of xenobiotic substrates and inhibitors of CYP26A1, CYP26B1 and CYP26C1 using computational modeling and in vitro analyses. Agricultural sciences. Université Nice Sophia Antipolis, 2016. English. NNT : 2016NICE4033. tel-01376678 HAL Id: tel-01376678 https://tel.archives-ouvertes.fr/tel-01376678 Submitted on 5 Oct 2016 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Université de Nice-Sophia Antipolis Thèse pour obtenir le grade de DOCTEUR DE L’UNIVERSITE NICE SOPHIA ANTIPOLIS Spécialité : Interactions Moléculaires et Cellulaires Ecole Doctorale : Sciences de la Vie et de la Santé (SVS) Caractérisation des substrats xénobiotiques et des inhibiteurs des cytochromes CYP26A1, CYP26B1 et CYP26C1 par modélisation moléculaire et études in vitro présentée et soutenue publiquement par Robert S. Foti Le 4 Juillet 2016 Membres du jury Dr. Danièle Werck-Reichhart Rapporteur Dr. Philippe Roche Rapporteur Pr. Serge Antonczak Examinateur Dr. Philippe Breton Examinateur Pr. Philippe Diaz Examinateur Dr. Dominique Douguet Directrice de thèse 1 1. Table of Contents 1. Table of Contents ..............................................................................................................................
    [Show full text]
  • Recent Advances in P450 Research
    The Pharmacogenomics Journal (2001) 1, 178–186 2001 Nature Publishing Group All rights reserved 1470-269X/01 $15.00 www.nature.com/tpj REVIEW Recent advances in P450 research JL Raucy1,2 ABSTRACT SW Allen1,2 P450 enzymes comprise a superfamily of heme-containing proteins that cata- lyze oxidative metabolism of structurally diverse chemicals. Over the past few 1La Jolla Institute for Molecular Medicine, San years, there has been significant progress in P450 research on many fronts Diego, CA 92121, USA; 2Puracyp Inc, San and the information gained is currently being applied to both drug develop- Diego, CA 92121, USA ment and clinical practice. Recently, a major accomplishment occurred when the structure of a mammalian P450 was determined by crystallography. Correspondence: Results from these studies will have a major impact on understanding struc- JL Raucy,La Jolla Institute for Molecular Medicine,4570 Executive Dr,Suite 208, ture-activity relationships of P450 enzymes and promote prediction of drug San Diego,CA 92121,USA interactions. In addition, new technologies have facilitated the identification Tel: +1 858 587 8788 ext 116 of several new P450 alleles. This information will profoundly affect our under- Fax: +1 858 587 6742 E-mail: jraucyȰljimm.org standing of the causes attributed to interindividual variations in drug responses and link these differences to efficacy or toxicity of many thera- peutic agents. Finally, the recent accomplishments towards constructing P450 null animals have afforded determination of the role of these enzymes in toxicity. Moreover, advances have been made towards the construction of humanized transgenic animals and plants. Overall, the outcome of recent developments in the P450 arena will be safer and more efficient drug ther- apies.
    [Show full text]
  • Pharmacogenetics of Cytochrome P450 and Its Application and Value in Drug Therapy – the Past, Present and Future
    Pharmacogenetics of cytochrome P450 and its application and value in drug therapy – the past, present and future Magnus Ingelman-Sundberg Karolinska Institutet, Stockholm, Sweden The human genome x 3,120,000,000 nucleotides x 23,000 genes x >100 000 transcripts (!) x up to 100,000 aa differences between two proteomes x 10,000,000 SNPs in databases today The majority of the human genome is transcribed and has an unknown function RIKEN consortium Science 7 Sep 2005 Interindividual variability in drug action Ingelman-Sundberg, M., J Int Med 250: 186-200, 2001, CYP dependent metabolism of drugs (80 % of all phase I metabolism of drugs) Tolbutamide Beta blokers Warfarin Antidepressants Phenytoin CYP2C9* Diazepam Antipsychotics NSAID Citalopram Dextromethorphan CYP2D6* CYP2C19* Anti ulcer drugs Codeine CYP2E1 Clozapine Debrisoquine CYP1A2 Ropivacaine CYP2B6* Efavirenz Cyclophosphamide CYP3A4/5/7 Cyclosporin Taxol Tamoxifen Tacrolimus 40 % of the phase I Amprenavir Amiodarone metabolism is Cerivastatin carried out by Erythromycin polymorphic P450s Methadone Quinine (enzymes in Italics) Phenotypes and mutations PM, poor metabolizers; IM, intermediate met; EM, efficient met; UM, ultrarapid met Frequency Population Homozygous based dosing for • Stop codons • Heterozygous Two funct deleterious • Deletions alleles SNPs • Deleterious • Gene missense • Unstable duplication SNPs protein • Induction • Splice defects EM PM IM UM Enzyme activity/clearance The Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee http://www.imm.ki.se/CYPalleles/ Webmaster: Sarah C Sim Editors: Magnus Ingelman-Sundberg, Ann K. Daly, Daniel W. Nebert Advisory Board: Jürgen Brockmöller, Michel Eichelbaum, Seymour Garte, Joyce A. Goldstein, Frank J. Gonzalez, Fred F. Kadlubar, Tetsuya Kamataki, Urs A.
    [Show full text]
  • Regulation of Cytochrome P450 (CYP) Genes by Nuclear Receptors Paavo HONKAKOSKI*1 and Masahiko NEGISHI† *Department of Pharmaceutics, University of Kuopio, P
    Biochem. J. (2000) 347, 321–337 (Printed in Great Britain) 321 REVIEW ARTICLE Regulation of cytochrome P450 (CYP) genes by nuclear receptors Paavo HONKAKOSKI*1 and Masahiko NEGISHI† *Department of Pharmaceutics, University of Kuopio, P. O. Box 1627, FIN-70211 Kuopio, Finland, and †Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology, NIEHS, National Institutes of Health, Research Triangle Park, NC 27709, U.S.A. Members of the nuclear-receptor superfamily mediate crucial homoeostasis. This review summarizes recent findings that in- physiological functions by regulating the synthesis of their target dicate that major classes of CYP genes are selectively regulated genes. Nuclear receptors are usually activated by ligand binding. by certain ligand-activated nuclear receptors, thus creating tightly Cytochrome P450 (CYP) isoforms often catalyse both formation controlled networks. and degradation of these ligands. CYPs also metabolize many exogenous compounds, some of which may act as activators of Key words: endobiotic metabolism, gene expression, gene tran- nuclear receptors and disruptors of endocrine and cellular scription, ligand-activated, xenobiotic metabolism. INTRODUCTION sex-, tissue- and development-specific expression patterns which are controlled by hormones or growth factors [16], suggesting Overview of the cytochrome P450 (CYP) superfamily that these CYPs may have critical roles, not only in elimination CYPs constitute a superfamily of haem-thiolate proteins present of endobiotic signalling molecules, but also in their production in prokaryotes and throughout the eukaryotes. CYPs act as [17]. Data from CYP gene disruptions and natural mutations mono-oxygenases, with functions ranging from the synthesis and support this view (see e.g. [18,19]). degradation of endogenous steroid hormones, vitamins and fatty Other mammalian CYPs have a prominent role in biosynthetic acid derivatives (‘endobiotics’) to the metabolism of foreign pathways.
    [Show full text]
  • Inhibition of Cytochrome P450 Enzymes
    7 Inhibition of Cytochrome P450 Enzymes Maria Almira Correia and Paul R. Ortiz de Monteflano 1. Introduction of P450 inhibitors are available in various reviews"^^^. This chapter focuses on the mecha­ Three steps in the catalytic cycle of nisms of inactivation; thus, most of the chapter is cytochrome P450 (P450, CYP; see Chapters 5 and devoted to the discussion of agents that require 6) are particularly vulnerable to inhibition: (a) the P450 catalysis to fiilfill their inhibitory potential. binding of substrates, (b) the binding of molecular The mechanisms of reversible competitive and oxygen subsequent to the first electron transfer, noncompetitive inhibitors, despite their practical and (c) the catalytic step in which the substrate is importance, are relatively straightforward and are actually oxidized. Only inhibitors that act at one of discussed more briefly. these three steps will be considered in this chapter. Inhibitors that act at other steps in the catalytic cycle, such as agents that interfere with the 2. Reversible Inhibitors electron supply to the hemoprotein by accepting electrons directly from P450 reductase^"^, are not Reversible inhibitors compete with substrates discussed here. for occupancy of the active site and include agents P450 inhibitors can be divided into three that (a) bind to hydrophobic regions of the active mechanistically distinct classes: Agents that site, (b) coordinate to the heme iron atom, or (a) bind reversibly, (b) form quasi-irreversible (c) enter into specific hydrogen bonding or ionic complexes with the heme iron atom, and (c) bind interactions with active-site residues"*"^^. The first irreversibly to the protein or the heme moiety, or mechanism, in which the inhibitor simply competes accelerate the degradation and/or oxidative frag­ for binding to lipophilic domains of the active site, mentation of the prosthetic heme.
    [Show full text]
  • Association of Warfarin Dose with Genes Involved in Its Action and Metabolism
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Springer - Publisher Connector Hum Genet (2007) 121:23–34 DOI 10.1007/s00439-006-0260-8 ORIGINAL INVESTIGATION Association of warfarin dose with genes involved in its action and metabolism Mia Wadelius · Leslie Y. Chen · Niclas Eriksson · Suzannah Bumpstead · Jilur Ghori · Claes Wadelius · David Bentley · Ralph McGinnis · Panos Deloukas Received: 6 July 2006 / Accepted: 1 September 2006 / Published online: 18 October 2006 © Springer-Verlag 2006 Abstract We report an extensive study of variability associated with dose (P < 0.05). VKORC1, CYP2C9, in genes encoding proteins that are believed to be CYP2C18 and CYP2C19 were signiWcant after involved in the action and biotransformation of warfa- experiment-wise correction for multiple testing rin. Warfarin is a commonly prescribed anticoagulant (P < 0.000175), however, the association of CYP2C18 that is diYcult to use because of the wide interindivid- and CYP2C19 was fully explained by linkage disequilib- ual variation in dose requirements, the narrow thera- rium with CYP2C9*2 and/or *3. PROC and APOE peutic range and the risk of serious bleeding. We were both signiWcantly associated with dose after cor- genotyped 201 patients for polymorphisms in 29 genes rection within each gene. A multiple regression model in the warfarin interactive pathways and tested them for with VKORC1, CYP2C9, PROC and the non-genetic association with dose requirement. In our study, poly- predictors age, bodyweight, drug interactions and indi- morphisms in or Xanking the genes VKORC1, CYP2C9, cation for treatment jointly accounted for 62% of vari- CYP2C18, CYP2C19, PROC, APOE, EPHX1, CALU, ance in warfarin dose.
    [Show full text]